@sponlinecoaching's TRT danger claims, fact-checked

What did @sponlinecoaching actually say?

The creator's core claim is simple: staying at low testosterone was more dangerous for him than starting TRT. He says his levels were "around four" on the UK range, describes poor liver values, bad blood lipids, mental health struggles, and excess body fat. After raising his levels to "around 28, 29," he says every one of those markers improved over roughly a year. He closes by promoting a blood test discount code and suggesting viewers can get prescribed TRT through the same company.

That's the full argument: personal bad health, TRT fixed it, go get tested. There's no mention of risks, no acknowledgment that his experience isn't universal, and no context around what those UK nmol/L numbers actually mean clinically.

Does the science back this up?

Partially, yes. The evidence that symptomatic hypogonadism responds to TRT is real and reasonably robust. But the claim that TRT universally improves metabolic markers is more complicated than a single anecdote suggests.

The landmark TRAVERSE trial (Lincoff et al., 2023, New England Journal of Medicine), the largest cardiovascular safety study of TRT to date with over 5,200 men, found that testosterone replacement did not increase major cardiovascular events compared to placebo in men with hypogonadism. That's reassuring. However, the same trial flagged elevated rates of atrial fibrillation, pulmonary embolism, and acute kidney injury in the testosterone group. Those signals matter.

On metabolic markers, a 2016 meta-analysis by Corona et al. in the Journal of Sexual Medicine found TRT modestly improved lipid profiles and reduced fat mass in hypogonadal men, which does align with the creator's experience. But liver values improving on TRT is not a well-documented phenomenon. Injected testosterone esters are not hepatotoxic the way oral androgens are, so his liver values improving is more likely explained by lifestyle changes, reduced alcohol, or weight loss that often accompanies TRT than by the testosterone itself.

What did they get wrong (or right)?

Credit where it's due: the creator is right that untreated hypogonadism carries real health consequences. Low testosterone is associated with increased cardiovascular risk, insulin resistance, depression, and reduced bone density. The idea that staying at a "rock bottom" level is itself a health risk is supported by the literature. A 2006 study by Laughlin et al. in Circulation found low endogenous testosterone was independently associated with higher cardiovascular mortality in older men.

What he got wrong, or at least dangerously incomplete, is presenting his outcome as the expected outcome. TRT comes with real tradeoffs. It suppresses endogenous production, often permanently. Fertility is impaired. Erythrocytosis, meaning elevated red blood cell count, is common and requires monitoring. The liver values claim is unsupported as a direct TRT mechanism. And the video ends with a direct-to-consumer blood test pitch that routes back to the same company that would prescribe him treatment, which is a financial conflict of interest the creator never discloses.

What should you actually know?

If your testosterone is genuinely low and symptomatic, TRT is a legitimate medical option. It is not experimental, and dismissing it entirely is as wrong as overselling it. But "low" means clinically deficient, not just below the upper range of normal. In the UK, NHS guidance generally requires levels below 8-12 nmol/L combined with symptoms before treatment is considered. A level of "around four" nmol/L with symptoms would meet most clinical thresholds, so the creator's treatment was almost certainly appropriate.

What you should not do is take a single person's health transformation story as your risk-benefit calculator. TRT requires baseline bloodwork, ongoing monitoring of hematocrit, PSA, lipids, and blood pressure, and a prescribing clinician who knows your full history. The TRAVERSE trial also specifically studied men aged 45 to 80 with pre-existing cardiovascular risk, so extrapolating its safety data to younger men or those without cardiac risk factors has limits.

Finally, any service that sells you a blood test and then offers to prescribe based on that same test has an obvious incentive structure you should account for when weighing their recommendation.